Compile Data Set for Download or QSAR
Report error Found 33 Enz. Inhib. hit(s) with all data for entry = 11420
TargetTyrosine-protein kinase BTK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM326211(3-[(3R)-1- acryloylpiperidin-3-yl]-1- (4-phenoxyph...)
Affinity DataIC50: 0.730nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613984(US11739090, Compound 7B)
Affinity DataIC50: 0.930nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613974(US11739090, Compound 5B | US11739090, Compound 3B)
Affinity DataIC50: 2.16nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613974(US11739090, Compound 5B | US11739090, Compound 3B)
Affinity DataIC50: 2.16nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613974(US11739090, Compound 5B | US11739090, Compound 3B)
Affinity DataIC50: 2.70nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Tec(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM326211(3-[(3R)-1- acryloylpiperidin-3-yl]-1- (4-phenoxyph...)
Affinity DataIC50: 3.39nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Tec(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613984(US11739090, Compound 7B)
Affinity DataIC50: 3.74nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613967(US11739090, Compound 2B)
Affinity DataIC50: 5.27nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613967(US11739090, Compound 2B)
Affinity DataIC50: 5.27nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613973(US11739090, Compound 3A)
Affinity DataIC50: 9.58nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613978(US11739090, Compound 6A)
Affinity DataIC50: 9.58nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613978(US11739090, Compound 6A)
Affinity DataIC50: 9.58nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613979(US11739090, Compound 4A)
Affinity DataIC50: 10nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613979(US11739090, Compound 4A)
Affinity DataIC50: 11nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613979(US11739090, Compound 4A)
Affinity DataIC50: 11nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM326211(3-[(3R)-1- acryloylpiperidin-3-yl]-1- (4-phenoxyph...)
Affinity DataIC50: 14.5nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613972(US11739090, Compound 5A)
Affinity DataIC50: 31.8nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613984(US11739090, Compound 7B)
Affinity DataIC50: 33.3nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Tec(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613967(US11739090, Compound 2B)
Affinity DataIC50: 42nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM326211(3-[(3R)-1- acryloylpiperidin-3-yl]-1- (4-phenoxyph...)
Affinity DataIC50: 42.2nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Tec(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613978(US11739090, Compound 6A)
Affinity DataIC50: 43.2nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Tec(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613974(US11739090, Compound 5B | US11739090, Compound 3B)
Affinity DataIC50: 74.8nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613982(US11739090, Compound 4B)
Affinity DataIC50: 98.1nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613981(US11739090, Compound 6B)
Affinity DataIC50: 140nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Tec(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613979(US11739090, Compound 4A)
Affinity DataIC50: 169nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613967(US11739090, Compound 2B)
Affinity DataIC50: 344nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613978(US11739090, Compound 6A)
Affinity DataIC50: 812nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613974(US11739090, Compound 5B | US11739090, Compound 3B)
Affinity DataIC50: 829nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613984(US11739090, Compound 7B)
Affinity DataIC50: 1.45E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613979(US11739090, Compound 4A)
Affinity DataIC50: 2.02E+3nMAssay Description:1. Reaction conditions: buffer conditions: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mm Na3VO4, 2 mm DTT, 1% DM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613974(US11739090, Compound 5B | US11739090, Compound 3B)
Affinity DataIC50: 5.43E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613978(US11739090, Compound 6A)
Affinity DataIC50: 7.32E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Jumbo Drug Bank

US Patent
LigandPNGBDBM613967(US11739090, Compound 2B)
Affinity DataIC50: 8.91E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2023
Entry Details
Go to US Patent